Gerresheimer Ag · XETR:GXI
Gerresheimer — Q3 2024 Earnings Presentation
17 slides from Gerresheimer's earnings presentation, Oct 10, 2024
Slide 1: Preliminary Q3/9M 2024 Results Presentation
Preliminary Q3/9M 2024 Results Presentation Dietmar Siemssen Dr. Bernd Metzner
Slide 2: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or
Slide 3: Preliminary Q3 2024 Review
Preliminary Q3 2024 Review Q3 2024: Growth driven by Plastics & Devices Organic Development: − Q4: Growth quarter ahead − P&D: High demand for drug with ramp-up of new lines Revenue growth: Adj. EBITDA growth: delivery systems: revenue +8%, Adj. EBITDA +11% − Lower than anticipated +2.6% +3.5% growt
Slide 4: Preliminary Q3 2024: Slight Growth Compared to Previous Year
Preliminary Q3 2024: Slight Growth Compared to Previous Year Operational View on KPIs in Q3 2024 Revenues Adj. EBITDA Adj. EPS (in EUR m) (in EUR m) (in EUR) Organic growth yoy: Organic growth yoy: Organic growth yoy: +2.6% +3.5% +3.6% 104 488 499 100 1.16 1.07 Q3 2023 Q3 2024 Q3 2023 Q3 2024 Q3 202
Slide 5: Preliminary Q3 2024: P&D with continued margin improvement
Preliminary Q3 2024: P&D with continued margin improvement Operational View on KPIs in Q3 2024 by Division Organic yoy In EUR m & margin Revenues Adj. EBITDA +7.9% +10.9% Margin improvement by 70bps 261 279 70 63 ▪ Organic revenue growth of 7.9% driven by strong demand for drug 25.1% P&D 24.4% deliv
Slide 6: Preliminary Q3 2024: Free Cash Flow Development as Expected
Preliminary Q3 2024: Free Cash Flow Development as Expected Cash Flow and Net Financial Debt In EUR m Q3 2024 Q3 2023 Adjusted EBITDA 104.4 100.0 Change in net working capital -3.6 74.3 Net interest paid -8.8 -5.4 Net taxes paid -14.7 -11.8 Other -6.1 1.8 Cash flow from operating activities 71.3 158
Slide 7: Near Term Guidance Update: Good Momentum but Recovery from Destocking Slower
Near Term Guidance Update: Good Momentum but Recovery from Destocking Slower than Initial Expectations ▪ Higher Growth in Q4: Robust growth in P&D - Return to growth in PPG ▪ However, slower than anticipated vial market recovery and some softness FY 2024 in F&B moulded glass ▪ Recent flooding in our
Slide 8: Guidance
Guidance FY 2024, FY 2025 and Mid-Term Guidance (organic; group level)* Revenue Growth Adjusted EBITDA Previous New Previous New Growth 415-430 FY 2024 3-4% EURm Growth ~22% FY 2025 7-10% Margin Mid-term No Change No Change * Adjusted EPS Growth for 2024 is expected to be between 2 and 8%; Adjusted
Slide 9: Continued Strong Conviction in Medium-Term Double-Digit Growth Ambition
Continued Strong Conviction in Medium-Term Double-Digit Growth Ambition and Robust Margin Expansion Trajectory 1 Bring the Drug to the Patient Bring the Drug into the Patient Improve Patient´s Health Outcome Strategic Partner of Choice for the Global Pharma and Biotech Industry Drug Containment Solu
Slide 10: Appendix
gerresheimer
Slide 11: Financial Calendar
Financial Calendar Annual General Meeting 2025 Publication 1rstQuarter 2025 Results Publication 4th Quarter/ Full-year 2024 Results Publication 3rd Quarter/ 9M 2024 Results June 5th, 2025 April 11th, 2025 February 26th, 2025 October 10th, 2024 11 10-Oct-2024 Gerresheimer AG - Prelim. Q3/9M 2024 Resu
Slide 12: Preliminary Q3 2024: Revenue & Organic Growth Reconciliation
Preliminary Q3 2024: Revenue & Organic Growth Reconciliation in EUR m organic gowth +2.6% -6.8 -0.4 499.3 -0.8 498.5 -0.5 20.4 487.9 -1.3 486.6 Revenue Q3 2023 FX Revenue Q3 P&D PPG GAT HQ, Cons. Revenue Q3 FX Revenue Q3 2024 2023 (organic) 2024 (organic) 12 10-Oct-2024 Gerresheimer AG - Prelim. Q3/
Slide 13: Preliminary Q3 2024: Adj. EBITDA & Organic Growth Reconciliation
Preliminary Q3 2024: Adj. EBITDA & Organic Growth Reconciliation in EUR m organic gowth 3.5% -4.7 104.2 0.2 104.4 6.9 2.5 -1.1 0.7 100.7 100.0 Adj. EBITDA FX Adj. EBITDA Q3 P&D PPG GAT HQ, Cons. Adj. EBITDA Q3 FX Adj. EBITDA Q3 2023 2023 (organic) 2024 (organic) Q3 2024 13 10-Oct-2024 Gerresheimer A
Slide 14: Reconciliation Preliminary Q3 2024: Reported and Adjusted Financials
Reconciliation Preliminary Q3 2024: Reported and Adjusted Financials Q3 2024 Q3 2023 Org. growth YoY1 In EUR m Reported Adjustment Adjusted Adjusted Adjusted Revenues 498.5 498.5 487.9 2.6% EBITDA 97.9 6.6 104.4 100.0 3.5% Depreciation & Amortization -49.5 9.8 -39.7 -34.7 EBIT 48.4 16.4 64.7 65.3 Fi
Slide 15: Reconciliation Preliminary 9M 2024: Reported and Adjusted Financials
Reconciliation Preliminary 9M 2024: Reported and Adjusted Financials 9M 2024 9M 2023 Org. growth YoY1 In EUR m Reported Adjustment Adjusted Adjusted Adjusted Revenues 1,467.0 1,467.0 1,445.3 2.0% EBITDA 278.9 13.8 292.7 285.2 3.1% Depreciation & Amortization -143.0 28.6 -114.4 -105.8 EBIT 135.9 42.4
Slide 16: Preliminary 9M 2024: Strong Cash Flow from Operating Activities
Preliminary 9M 2024: Strong Cash Flow from Operating Activities Cash Flow and Net Financial Debt In EUR m 9M 2024 9M 2023 Adjusted EBITDA 292.7 285.2 Change in net working capital -77.6 -38.5 Net interest paid -28.7 -20.9 Net taxes paid -30.8 -43.6 Other -35.3 -37.2 Cash flow from operating activiti
Slide 17: innovating for a better life
innovating for a better life